

Final Appraisal Recommendation

Advice No: 3315 – November 2015

Sucroferric oxyhydroxide (Velphoro[®]▼) 500 mg chewable tablets

Submission by Fresenius Medical Care UK Ltd

Recommendation of AWMSG

Sucroferric oxyhydroxide (Velphoro[®]▼) is recommended as an option for restricted use within its licensed indication within NHS Wales for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Sucroferric oxyhydroxide (Velphoro[®]▼) should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease.

Sucroferric oxyhydroxide (Velphoro[®]▼) should be restricted as an option for use where non-calcium based phosphate binders are considered appropriate.

Sucroferric oxyhydroxide (Velphoro[®]▼) is not recommended for use within NHS Wales outside of this subpopulation.

Additional note(s):

- The cost-effectiveness evidence provided by the applicant company was limited to second-line use in adults whose serum phosphorus levels are not controlled with a calcium-based binder or who are controlled but have high serum calcium levels or low serum parathyroid levels, in line with the recommendations for the use of non-calcium phosphate binders in guidelines for hyperphosphataemia in chronic kidney disease.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1504), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

| | |
|-----------------------------------------------|-------------------------------|
| Marketing authorisation holder on first issue | Fresenius Medical Care UK Ltd |
| Date of first issue | November 2015 |
| Last reviewed | March 2019 |



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3315
Sucroferric oxyhydroxide (Velphoro[®]) 500 mg chewable tablets. November 2015.

